

MD7510 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies (DL)

View Online



1.

Diagnosis and management of type 1 diabetes in children, young people and adults | Guidance and guidelines | NICE. <https://www.nice.org.uk/guidance/cg15>

2.

Type 2 diabetes in adults: management | Guidance and guidelines | NICE. <https://www.nice.org.uk/guidance/ng28>

3.

Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis. <http://onlinelibrary.wiley.com.ezproxy3.lib.le.ac.uk/doi/10.1111/dom.12849/epdf>

4.

Obesity: identification, assessment and management | Guidance and guidelines | NICE. <https://www.nice.org.uk/guidance/cg189>

5.

Managing Older People with Type 2 Diabetes: IDF Global Guideline - International Federation on Ageing. <https://www.ifa-fiv.org/managing-older-people-with-type-2-diabetes-idf-global-guideline/>

6.

NHS Evidence: an introduction.

http://www.solent.nhs.uk/_store/documents/nhs_evidence_guide.pdf

7.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes. 5th ed. John Wiley & Sons, Incorporated; 2016.

<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

8.

Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010.

<http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

9.

Atkinson MA. The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine. 2012;2(11):a007641-a007641.

doi:10.1101/cshperspect.a007641

10.

Jelinek HF, Stranieri A, Yatsko A, Venkatraman S. Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. Computers in Biology and Medicine. 2016;75:90-97. doi:10.1016/j.combiomed.2016.05.005

11.

S M Attard. Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. Nutrition & Diabetes. 2015;5(6). doi:doi: 10.1038/nutd.2015.16

12.

Samuel VT, Shulman GI. Integrating Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell. 2012;148(5):852-871. doi:10.1016/j.cell.2012.02.017

13.

Beverley M Shields. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. *BMJ Open*. 2015;5(11). doi:doi:10.1136/bmjopen-2015-009088

14.

Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. *Postgraduate Medical Journal*. 2016;92(1084):63-69. doi:10.1136/postgradmedj-2015-133281

15.

Anthony H. Barnett, Jenny Grice. *New Mechanisms in Glucose Control*. BMJ Books; 1 edition; 2013. <http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133>

16.

Gregg EW. The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016. *Diabetes Care*. Published online 10 August 2017. doi:10.2337/dci16-0055

17.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes*. 5th ed. John Wiley & Sons, Incorporated; 2016. <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

18.

Holt RIG. *Textbook of Diabetes*. 4th ed. Wiley-Blackwell; 2010. <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

19.

Copeland KC, Silverstein J, Moore KR, et al. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. *PEDIATRICS*. 2013;131(2):364-382. doi:10.1542/peds.2012-3494

20.

Kenneth Hodson. Gestational diabetes: emerging concepts in pathophysiology. *Obstetric Medicine*. 2010;3(4). doi:doi: 10.1258/om.2010.100025

21.

Latika Sahu. Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. *Obstetric Medicine*. 2009;2(4). doi:doi: 10.1258/om.2009.080049

22.

Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR, Aguilar RB. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β -Cell-Centric Classification Schema. *Diabetes Care*. 2016;39(2):179-186. doi:10.2337/dc15-1585

23.

Nolan CJ, Ruderman NB, Kahn SE, Pedersen O, Prentki M. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. *Diabetes*. 2015;64(3):673-686. doi:10.2337/db14-0694

24.

Gale EA. Is type 2 diabetes a category error? *The Lancet*. 2013;381(9881):1956-1957. doi:10.1016/S0140-6736(12)62207-7

25.

Moreno-Castilla C, Mauricio D, Hernandez M. Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. *Current Diabetes Reports*. 2016;16(4). doi:10.1007/s11892-016-0717-7

26.

Noctor E, Dunne F. Postnatal testing following gestational diabetes. *The Lancet Diabetes &*

Endocrinology. 2015;3(10):761-762. doi:10.1016/S2213-8587(15)00322-8

27.

Birkeland KI. Hyperglycaemia in pregnancy: still a lot to learn. *The Lancet Diabetes & Endocrinology*. 2015;3(10):752-753. doi:10.1016/S2213-8587(15)00282-X

28.

Rinki Murphy. Monogenic diabetes and pregnancy. *Obstetric Medicine*. 2015;8(3). doi:doi:10.1177/1753495X15590713

29.

Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. *New England Journal of Medicine*. 2016;375(7):644-654. doi:10.1056/NEJMoa1602494

30.

Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3). <https://www.nice.org.uk/guidance/ng3>

31.

Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. *Diabetic Medicine*. 2013;30(7):803-817. doi:10.1111/dme.12159

32.

Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care.
<http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>

33.

Brown J, Alwan NA, West J, et al. Lifestyle interventions for the treatment of women with gestational diabetes. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; 1996. doi:10.1002/14651858.CD011970.pub2

34.

Rasouli B, Andersson T, Carlsson PO, et al. Serious life events and the risk of latent autoimmune diabetes in adults (LADA) and Type 2 diabetes. *Diabetic Medicine*. 2017;34(9):1259-1263. doi:10.1111/dme.13410

35.

Davies M, Dahl D, Heise T, Kiljanski J, Mathieu C. Introduction of biosimilar insulins in Europe. *Diabetic Medicine*. 2017;34(10):1340-1353. doi:10.1111/dme.13400

36.

Perrin NE, Davies MJ, Robertson N, Snoek FJ, Khunti K. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. *Diabetic Medicine*. 2017;34(11):1508-1520. doi:10.1111/dme.13448

37.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes*. 5th ed. John Wiley & Sons, Incorporated; 2016.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

38.

Holt RIG. *Textbook of Diabetes*. 4th ed. Wiley-Blackwell; 2010.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

39.

Standards of Medical Care in Diabetes--2015: Summary of Revisions. *Diabetes Care*. 2015;38(Supplement_1):S4-S4. doi:10.2337/dc15-S003

40.

A Randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study.
<http://www.journalslibrary.nihr.ac.uk/hta/volume-20/issue-64#abstract>

41.

Kamlesh Khunti. Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. PLoS ONE. 2015;10(9). doi:doi: 10.1371/journal.pone.0135702

42.

Tao L, Wilson ECF, Wareham NJ, et al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabetic Medicine. 2015;32(7):907-919. doi:10.1111/dme.12711

43.

Gray LJ, Khunti K, Wilmot EG, Yates T, Davies MJ. External validation of two diabetes risk scores in a young UK South Asian population. Diabetes Research and Clinical Practice. 2014;104(3):451-458. doi:10.1016/j.diabres.2014.03.018

44.

Gray LJ, Khunti K, Edwardson C, et al. Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. Diabetologia. 2012;55(12):3238-3244. doi:10.1007/s00125-012-2725-8

45.

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149. doi:10.2337/dc14-2441

46.

Guidelines. <https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes>

47.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes. 5th ed. John Wiley & Sons, Incorporated; 2016.

<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

48.

Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010.

<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

49.

Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010.

<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

50.

Davies MJ, Heller S, Skinner TC, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. *BMJ*. 2008;336(7642):491-495. doi:10.1136/bmj.39474.922025.BE

51.

Johnston BC, Kanters S, Bandayrel K, et al. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. *JAMA*. 2014;312(9).

doi:10.1001/jama.2014.10397

52.

Steven S, Hollingsworth KG, Al-Mrabeh A, et al. Very Low-Calorie Diet and 6 Months of

Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. *Diabetes Care*. 2016;39(5):808-815. doi:10.2337/dc15-1942

53.

Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. *Diabetic Medicine*. 2015;32(9):1149-1155. doi:10.1111/dme.12722

54.

Amy Kennedy. Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. *PLoS ONE*. 2013;8(3). doi:doi: 10.1371/journal.pone.0058861

55.

Chimen M, Kennedy A, Nirantharakumar K, Pang TT, Andrews R, Narendran P. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. *Diabetologia*. 2012;55(3):542-551. doi:10.1007/s00125-011-2403-2

56.

Umpierre D. Physical Activity Advice Only or Structured Exercise Training and Association With HbA_{1c} Levels in Type 2 Diabetes. *JAMA*. 2011;305(17). doi:10.1001/jama.2011.576

57.

Avery L, Flynn D, van Wersch A, Sniehotta FF, Trenell MI. Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. *Diabetes Care*. 2012;35(12):2681-2689. doi:10.2337/dc11-2452

58.

Barry VW, Baruth M, Beets MW, Durstine JL, Liu J, Blair SN. Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. *Progress in Cardiovascular Diseases*. 2014;56(4):382-390. doi:10.1016/j.pcad.2013.09.002

59.

Qin L, Knol MJ, Corpeleijn E, Stolk RP. Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. *European Journal of Epidemiology*. 2010;25(1):5-12. doi:10.1007/s10654-009-9395-y

60.

Lee IM. Physical Activity and Weight Gain Prevention. *JAMA*. 2010;303(12). doi:10.1001/jama.2010.312

61.

John M Jakicic. Physical activity considerations for the treatment and prevention of obesity. *The American Journal of Clinical Nutrition*. 2005;82(1):226S-229S. <http://ajcn.nutrition.org/content/82/1/226S>

62.

Heinonen I, Helajärvi H, Pahkala K, et al. Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. *BMJ Open*. 2013;3(6). doi:10.1136/bmjopen-2013-002901

63.

Sallis JF, Bull F, Guthold R, et al. Progress in physical activity over the Olympic quadrennium. *The Lancet*. 2016;388(10051):1325-1336. doi:10.1016/S0140-6736(16)30581-5

64.

Yeh JS, Kushner RF, Schiff GD. Obesity and Management of Weight Loss. *New England Journal of Medicine*. 2016;375(12):1187-1189. doi:10.1056/NEJMclde1515935

65.

Henson, Joseph. Associations of Sedentary Time with Fat Distribution in a High-Risk

Population. Published online 10 November 2014. <https://lra.le.ac.uk/handle/2381/32505>

66.

The Eatwell Guide. Public Health England; 2016.
<https://www.gov.uk/government/publications/the-eatwell-guide>

67.

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review) TA151, July 2008. <http://www.nice.org.uk/guidance/ta151>

68.

Hadjiconstantinou M, Byrne J, Bodicoat DH, et al. Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. *Journal of Medical Internet Research*. 2016;18(10). doi:10.2196/jmir.5991

69.

Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. *Diabetes Care* 2016;39:2126–2140. *Diabetes Care*. 2017;40(2):287.1-287. doi:10.2337/dc17-er02

70.

Capehorn M, Polonsky WH, Edelman S, et al. Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia). *Diabetic Medicine*. Published online March 2017. doi:10.1111/dme.13357

71.

Hartman YAW, Jansen HJ, Hopman MTE, Tack CJ, Thijssen DHJ. Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. *Diabetes Care* . 2017;40(9):e120-e121. doi:10.2337/dc17-0787

72.

Hessler DM, Fisher L, Polonsky WH, et al. Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes. *Diabetic Medicine*. 2017;34(9):1228-1234. doi:10.1111/dme.13381

73.

Ferrari M, Dal Cin M, Steele M. Self-compassion is associated with optimum self-care behaviour, medical outcomes and psychological well-being in a cross-sectional sample of adults with diabetes. *Diabetic Medicine*. 2017;34(11):1546-1553. doi:10.1111/dme.13451

74.

William H. Polonsky, Lawrence Fisher, Jay Earles, R. James Dudl, Joel Lees, Joseph Mullan. Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. *Diabetes Care*.
http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm¤tPosition=25&docId=GALE%7CA130282980&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA130282980&searchId=R15&userGroupName=leicester&inPS=true

75.

Constructs of depression and distress in diabetes: time for an appraisal- *ClinicalKey*.
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858715001357>

76.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes*. 5th ed. John Wiley & Sons, Incorporated; 2016.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

77.

Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

78.

Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. *The Lancet*. 2012;380(9840):475-483. doi:10.1016/S0140-6736(12)60691-6

79.

Rizos CV, Kei A, Elisaf MS. The current role of thiazolidinediones in diabetes management. *Archives of Toxicology*. 2016;90(8):1861-1881. doi:10.1007/s00204-016-1737-4

80.

Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. *New England Journal of Medicine*. 2007;356(24):2457-2471. doi:10.1056/NEJMoa072761

81.

Tanner M. Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. *Annals of Internal Medicine*. 2016;165(4). doi:10.7326/ACPJC-2016-165-4-020

82.

Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulphonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*. 2015;109(2):378-388. doi:10.1016/j.diabres.2015.05.025

83.

Bennett WL, Maruthur NM, Singh S, et al. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. *Annals of Internal Medicine*. 2011;154(9).

doi:10.7326/0003-4819-154-9-201105030-00336

84.

Merlin C. Thomas. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. *Diabetes Therapy*. 2016;7(3). doi:doi: 10.1007/s13300-016-0189-4

85.

Paul Craddy. Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. *Diabetes Therapy*. 2014;5(1). doi:doi: 10.1007/s13300-014-0061-3

86.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes*. 5th ed. John Wiley & Sons, Incorporated; 2016.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

87.

Holt RIG. *Textbook of Diabetes*. 4th ed. Wiley-Blackwell; 2010.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

88.

Ryder B, McKnight J, Blann A, et al. ABCD position statement on GLP-1 based therapies and pancreatic damage. *Practical Diabetes*. 2013;30(9):388-391. doi:10.1002/pdi.1816

89.

Amori RE, Lau J, Pittas AG. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. *JAMA*. 2007;298(2). doi:10.1001/jama.298.2.194

90.

Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *The Lancet*. 2009;374(9683):39-47. doi:10.1016/S0140-6736(09)60659-0

91.

Type 2 diabetes: prevention in people at high risk | Guidance and guidelines | NICE.
<http://www.nice.org.uk/guidance/PH38>

92.

Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. *Diabetes Care*. 2010;33(6):1255-1261. doi:10.2337/dc09-1914

93.

Buse JB, Bergenstal RM, Glass LC, et al. Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine*. 2011;154(2). doi:10.7326/0003-4819-154-2-201101180-00300

94.

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *The Lancet*. 2010;375(9733):2223-2233. doi:10.1016/S0140-6736(10)60407-2

95.

Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*. 2010;375(9733):2234-2243. doi:10.1016/S0140-6736(10)60406-0

96.

Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in

patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes, Obesity and Metabolism*. 2007;9(2):194-205. doi:10.1111/j.1463-1326.2006.00704.x

97.

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | 1-Recommendations | Guidance and guidelines | NICE.
<https://www.nice.org.uk/guidance/ta390/chapter/1-Recommendations>

98.

Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*. Published online 15 September 2016. doi:10.1056/NEJMoa1607141

99.

Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. *The Lancet Diabetes & Endocrinology*. 2016;4(6):525-536. doi:10.1016/S2213-8587(15)00482-9

100.

Type 2 diabetes: lixisenatide | Evidence-review | Advice | NICE.
<https://www.nice.org.uk/advice/esnm26/chapter/evidence-review>

101.

Dapagliflozin in combination therapy for treating type 2 diabetes June 2013.
<http://www.nice.org.uk/guidance/ta288>

102.

Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes | Guidance and guidelines TA 248 Feb 2015.
<https://www.nice.org.uk/guidance/ta248>

103.

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010.
<https://www.nice.org.uk/guidance/ta203>

104.

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2016;375(4):311-322.
doi:10.1056/NEJMoa1603827

105.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2016;375(18):1797-1799. doi:10.1056/NEJMc1611289

106.

Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*. 2016;375(4):323-334.
doi:10.1056/NEJMoa1515920

107.

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*. 2016;375(18):1799-1802. doi:10.1056/NEJMc1611290

108.

Courtney H, Nayar R, Rajeswaran C, Jandhyala R. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2017;Volume 10:79-87. doi:10.2147/DMSO.S126763

109.

Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes

in Type 2 Diabetes. *New England Journal of Medicine*. 2015;373(3):232-242.
doi:10.1056/NEJMoa1501352

110.

Rotz ME, Ganetsky VS, Sen S, Thomas TF. Implications of incretin-based therapies on cardiovascular disease. *International Journal of Clinical Practice*. 2015;69(5):531-549.
doi:10.1111/ijcp.12572

111.

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2016;375(4):311-322.
doi:10.1056/NEJMoa1603827

112.

Levin PA, Nguyen H, Wittbrodt E, Kim SC. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2017;Volume 10:123-139. doi:10.2147/DMSO.S130834

113.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes*. 5th ed. John Wiley & Sons, Incorporated; 2016.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

114.

Holt RIG. *Textbook of Diabetes*. 4th ed. Wiley-Blackwell; 2010.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

115.

Leff DR, Heath D. Surgery for obesity in adulthood. *BMJ*. 2009;339(sep22 1):b3402-b3402.
doi:10.1136/bmj.b3402

116.

Schauer PR, Kashyap SR, Wolski K, et al. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. *New England Journal of Medicine*. 2012;366(17):1567-1576. doi:10.1056/NEJMoa1200225

117.

Riddle MC, Aronson R, Home P, et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care*. 2013;36(9):2489-2496. doi:10.2337/dc12-2454

118.

Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. *New England Journal of Medicine*. 2004;351(26):2683-2693. doi:10.1056/NEJMoa035622

119.

Persaud SJ, Jones PM. A Wake-up Call for Type 2 Diabetes? *New England Journal of Medicine*. 2016;375(11):1090-1092. doi:10.1056/NEJMcibr1607950

120.

Fagin JA, Wells SA. Biologic and Clinical Perspectives on Thyroid Cancer. *New England Journal of Medicine*. 2016;375(11):1054-1067. doi:10.1056/NEJMra1501993

121.

National Obesity Observatory. <http://www.noo.org.uk>

122.

Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine*. 2017;376(7):641-651. doi:10.1056/NEJMoa1600869

123.

Min SH, Yoon JH, Hahn S, Cho YM. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. *Diabetes/Metabolism Research and Reviews*. 2017;33(1). doi:10.1002/dmrr.2818

124.

Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. *The Lancet*. 2014;384(9951):1349-1357. doi:10.1016/S0140-6736(14)60976-4

125.

Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). *Diabetes Care*. 2014;37(8):2149-2158. doi:10.2337/dc13-2761

126.

Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine*. 2017;376(7):641-651. doi:10.1056/NEJMoa1600869

127.

Bethel MA, Engel SS, Green JB, et al. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). *Diabetes Care*. 2017;40(4):494-501. doi:10.2337/dc16-1135

128.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes*. 5th ed. John Wiley & Sons, Incorporated; 2016.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

129.

Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

130.

Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. *New England Journal of Medicine*. 2010;363(4):311-320. doi:10.1056/NEJMoa1002853

131.

Choudhary P, Parrott NR, Birtles L, Rutter MK. Islet cell transplantation: current status in the UK (2012). *Practical Diabetes*. 2012;29(7):280-285. doi:10.1002/pdi.1707

132.

Pickup JC. Insulin-Pump Therapy for Type 1 Diabetes Mellitus. *New England Journal of Medicine*. 2012;366(17):1616-1624. doi:10.1056/NEJMct1113948

133.

Srinivasan P, Huang GC, Amiel SA, Heaton ND. Islet cell transplantation. *Postgraduate Medical Journal*. 2007;83(978):224-229. doi:10.1136/pgmj.2006.053447

134.

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010.
<https://www.nice.org.uk/guidance/ta203>

135.

Villani M, de Courten B, Zoungas S. Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine*. 2017;34(9):1205-1211. doi:10.1111/dme.13379

136.

Dhatariya KK, Skedgel C, Fordham R. The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. *Diabetic Medicine*. 2017;34(10):1361-1366. doi:10.1111/dme.13427

137.

Leelarathna L, Roberts SA, Hindle A, et al. Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. *Diabetic Medicine*. 2017;34(10):1372-1379. doi:10.1111/dme.13412

138.

Yates T, Davies MJ. Physical activity and Type 1 diabetes: an underused therapy. *Diabetic Medicine*. 2017;34(11):1498-1499. doi:10.1111/dme.13445

139.

Narendran P, Jackson N, Daley A, et al. Exercise to preserve β -cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial. *Diabetic Medicine*. 2017;34(11):1521-1531. doi:10.1111/dme.13439

140.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes*. 5th ed. John Wiley & Sons, Incorporated; 2016.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

141.

Holt RIG. *Textbook of Diabetes*. 4th ed. Wiley-Blackwell; 2010.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

142.

Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the

Role for Continuous Glucose Monitoring. *Journal of diabetes science and technology* (Online). 3(4). <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/>

143.

Minimizing Hypoglycemia in Diabetes: Table 1. *Diabetes Care*. 2015;38(8):1583-1591. doi:10.2337/dc15-0279

144.

[ARCHIVED CONTENT] Medicines management: Everybody's business : Department of Health - Publications and statistics. http://webarchive.nationalarchives.gov.uk/20080205132320/http://dh.gov.uk/en/publication/sandstatistics/publications/publicationspolicyandguidance/dh_082200

145.

Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. CG76, Jan 2009. <https://www.nice.org.uk/guidance/cg76>

146.

Grammes J, Stock W, Mann CG, Flynn EM, Kubiak T. Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. *Diabetic Medicine*. Published online 30 August 2017. doi:10.1111/dme.13506

147.

Sivasubramaniam S, Amiel SA, Choudhary P. Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. *Diabetic Medicine*. 2017;34(10):1456-1460. doi:10.1111/dme.13438

148.

Vloemans AF, van Beers CAJ, de Wit M, et al. Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. *Diabetic Medicine*. 2017;34(10):1470-1476. doi:10.1111/dme.13429

149.

Harman-Boehm I. Continuous glucose monitoring in type 2 diabetes. *Diabetes Research and Clinical Practice*. 2008;82:S118-S121. doi:10.1016/j.diabres.2008.09.051

150.

Bailey, Stephen. *Academic Writing : A Handbook for International Students*.
<http://lib.mylibrary.com.ezproxy4.lib.le.ac.uk/Open.aspx?id=310467>

151.

Crete P, Lea MR. *Writing At University: A Guide For Students*. 3rd ed. McGraw-Hill Education; 2008.
<https://ebookcentral.proquest.com/lib/leicester/detail.action?pq-origsite=primo&docID=345134>